sorafenib has been researched along with lu 208075 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (lu 208075) | Trials (lu 208075) | Recent Studies (post-2010) (lu 208075) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 298 | 54 | 227 |
| Protein | Taxonomy | sorafenib (IC50) | lu 208075 (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | 0.195 | |
| Endothelin receptor type B | Homo sapiens (human) | 0.6925 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0114 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for sorafenib and lu 208075
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |